Cardiovascular Drugs Practice Questions

Q: What is the drug of choice for ventricular arrhythmia due to myocardial infarction?

Lidocaine. **Explanation:** **Lidocaine (Option C)** is the drug of choice for treating acute ventricular arrhythmias (VT/VF) specifically occurring in the setting of **Myocardial Infarction (MI)**. As a Class IB anti-arrhythmic, it works by blocking voltage-gated sodium channels. Its unique clinical utility lies in its high affinity for channels in the **depolarized/ischemic state**. In the acidic and hypoxic environment of an MI, lidocaine binds rapidly to inactivated channels, effectively suppressing ectopic foci in the ischemic zone while having minimal effect on normal, healthy myocardial tissue. **Why other options are incorrect:** * **Quinidine (Option A):** A Class IA agent that prolongs the QT interval. It is contraindicated in MI because it can increase mortality and predispose patients to *Torsades de Pointes*. * **Amiodarone (Option B):** While it is the drug of choice for hemodynamically unstable VT/VF in general Advanced Cardiovascular Life Support (ACLS), Lidocaine remains the classic "textbook" answer for arrhythmias specifically triggered by acute ischemia/MI due to its tissue-specific action. * **Phenytoin (Option D):** A Class IB agent primarily used for **Digitalis-induced arrhythmias**, not for routine post-MI management. **High-Yield Pearls for NEET-PG:** * **Route:** Lidocaine must be given **IV** due to extensive first-pass metabolism. * **Toxicity:** Overdose leads to CNS side effects, most notably **seizures**. * **Prophylaxis:** Prophylactic use of Lidocaine in MI is **not recommended** as it may increase the risk of asystole; it is only used for active arrhythmia management. * **Mexiletine** is the orally active analog of Lidocaine.

Q: Which of the following is FALSE about Aliskiren?

It is a p-glycoprotein inhibitor. **Explanation:** **Aliskiren** is the first orally active **Direct Renin Inhibitor (DRI)**. Understanding its mechanism and pharmacokinetics is crucial for NEET-PG. **Why Option C is the correct (False) statement:** Aliskiren is actually a **substrate** of P-glycoprotein (P-gp), not an inhibitor. Drugs that inhibit P-gp (like Ketoconazole, Cyclosporine, or Verapamil) can significantly increase the plasma concentration of Aliskiren, leading to toxicity. It does not inhibit the transporter itself. **Analysis of Incorrect Options:** * **Option A (True):** Aliskiren is the only clinically used **oral** direct renin inhibitor. It has low bioavailability (~2.5%), which is further reduced by high-fat meals. * **Option B (True):** Like ACE inhibitors and ARBs, Aliskiren reduces Aldosterone secretion. This leads to potassium retention, potentially causing **hyperkalemia**, especially when used in patients with renal impairment or those taking potassium-sparing diuretics. * **Option D (True):** This is its primary mechanism of action. By binding to the active site of Renin, it prevents the rate-limiting step of the RAAS cascade: the conversion of **Angiotensinogen to Angiotensin I**. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindication:** Aliskiren is strictly contraindicated in **pregnancy** (teratogenic) and should not be combined with ACE inhibitors or ARBs in patients with **Diabetes Mellitus** due to increased risk of stroke and renal damage (ALTITUDE trial). * **Effect on PRA:** Unlike ACE inhibitors/ARBs which increase Plasma Renin Activity (PRA) via feedback, Aliskiren **decreases PRA**. * **Side Effects:** Apart from hyperkalemia, it can cause GI disturbances like **diarrhea** (at high doses) and angioedema (rare).

Q: Trimetazidine is used for which of the following conditions?

Angina. **Explanation:** **Trimetazidine** is a unique anti-anginal agent classified as a **pFOX (partial Fatty Acid Oxidation) inhibitor**. 1. **Why Angina is Correct:** Trimetazidine acts as a **metabolic modulator**. It inhibits the enzyme **3-ketoacyl-CoA thiolase (3-KAT)**, which shifts the myocardial metabolism from fatty acid oxidation to **glucose oxidation**. Since glucose oxidation requires less oxygen to produce the same amount of ATP compared to fatty acids, the drug improves myocardial energy efficiency. This protects the heart from ischemic injury without affecting heart rate or blood pressure, making it an effective add-on therapy for **Stable Angina Pectoris**. 2. **Why Other Options are Incorrect:** * **Hypertension:** Trimetazidine has no vasodilator properties and does not affect systemic vascular resistance; hence, it is not used for hypertension. * **CHF:** While metabolic support is beneficial, Trimetazidine is not a primary treatment for CHF. Standard therapy involves ACE inhibitors, Beta-blockers, and Diuretics. * **Arrhythmia:** It does not block ion channels (Sodium, Potassium, or Calcium) and thus lacks anti-arrhythmic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits 3-KAT enzyme → Shifts metabolism to glucose → Preserves ATP levels during ischemia. * **Hemodynamics:** It is a "pure" metabolic agent; it does **not** alter heart rate, blood pressure, or double product. * **Side Effects:** Can cause **Parkinsonian symptoms** (tremors, rigidity) and gait disturbances; it is contraindicated in patients with Parkinson’s disease. * **Similar Drug:** **Ranolazine** also acts on myocardial metabolism but primarily works by inhibiting the **late sodium current ($I_{Na}$)**.

Q: Which of the following drugs can increase the calcium sensitivity of myocytes?

Levosimendan. ### Explanation **Correct Option: B. Levosimendan** Levosimendan belongs to a class of drugs known as **Calcium Sensitizers**. It exerts its positive inotropic effect by binding to **Troponin C** in a calcium-dependent manner. This stabilizes the calcium-induced conformational change in the troponin complex, increasing the sensitivity of myofilaments to existing calcium without increasing the actual intracellular calcium concentration. Levosimendan has been approved for use in acute failure in Europe and has shown noninferiority against dobutamine [1]. This is clinically significant because it enhances myocardial contractility without increasing myocardial oxygen demand or causing arrhythmias associated with calcium overload. Additionally, it acts as a vasodilator by opening ATP-sensitive potassium channels. **Incorrect Options:** * **A. Omapatrilat:** This is a Vasopeptidase inhibitor that inhibits both Neprilysin and ACE. It was developed for hypertension and heart failure but is not a calcium sensitizer. * **C. Milrinone:** This is a **PDE-3 inhibitor**. It increases cAMP levels, which leads to an *increase* in intracellular calcium levels in myocytes [2]. While it is an inodilator, its mechanism is distinct from calcium sensitization. * **D. Sacubitril:** This is a **Neprilysin inhibitor** used in combination with Valsartan (ARNI) for heart failure [3]. It prevents the degradation of natriuretic peptides but has no direct effect on myocyte calcium sensitivity. **High-Yield Facts for NEET-PG:** * **Levosimendan Triple Action:** 1. Inotropy (Troponin C binding), 2. Vasodilation ($K_{ATP}$ channel opening), 3. Cardioprotection (mitochondrial $K_{ATP}$ channels). * **Advantage:** Unlike Dobutamine or Milrinone, Levosimendan does not increase the risk of calcium-induced arrhythmias. * **Pimobendan:** Another calcium sensitizer often mentioned in this category. * **Clinical Use:** Primarily used in acute decompensated heart failure.

Q: Which anti-androgen is used in heart failure?

Spironolactone. **Explanation:** **Spironolactone** is the correct answer because it is a **Mineralocorticoid Receptor Antagonist (MRA)**. While primarily used in heart failure to block the deleterious effects of aldosterone on the myocardium (preventing cardiac fibrosis and remodeling), it is chemically a steroid derivative with significant **anti-androgenic properties**. It acts as a competitive antagonist at the androgen receptor and inhibits 17α-hydroxylase, leading to side effects like gynecomastia and decreased libido, which are high-yield clinical markers for this drug. **Analysis of Options:** * **A. Carvedilol:** A non-selective beta-blocker with alpha-1 blocking activity. While it is a cornerstone in heart failure management (reducing mortality), it has no anti-androgenic activity. * **B. Sampatrilat:** A dual inhibitor of Angiotensin-Converting Enzyme (ACE) and Neutral Endopeptidase (NEP). It was studied for heart failure and hypertension but is not classified as an anti-androgen. * **D. Abiraterone:** A potent anti-androgen (CYP17 inhibitor) used in metastatic castration-resistant prostate cancer. It is **not** used to treat heart failure; in fact, it can cause fluid retention and hypertension due to mineralocorticoid excess. **High-Yield Clinical Pearls for NEET-PG:** * **RALES Trial:** Demonstrated that Spironolactone reduces mortality in NYHA Class III and IV heart failure. * **Eplerenone:** A more selective MRA with fewer anti-androgenic side effects (less gynecomastia) compared to Spironolactone. * **Potassium Sparing:** Both are potassium-sparing diuretics; the most critical side effect to monitor is **hyperkalemia**, especially when combined with ACE inhibitors or ARBs.

Q: Which of the following drug classes has both anti-arrhythmic and anti-anginal properties?

Beta blockers. **Explanation:** **Beta-blockers (Option A)** are the correct choice because they possess dual therapeutic utility in managing both arrhythmias and angina pectoris. * **Anti-anginal mechanism:** They reduce myocardial oxygen demand by decreasing heart rate (negative chronotropy), blood pressure, and myocardial contractility (negative inotropy). This increases diastolic perfusion time, improving coronary blood flow. * **Anti-arrhythmic mechanism:** Classified as **Vaughan-Williams Class II** anti-arrhythmics, they block sympathetic stimulation of the heart. This decreases the slope of Phase 4 depolarization in SA/AV nodes, thereby suppressing automaticity and slowing AV conduction. **Why other options are incorrect:** * **Nitrates (Option B):** These are potent vasodilators used primarily for angina (reducing preload). They have no direct anti-arrhythmic properties and can actually cause reflex tachycardia, which may worsen certain arrhythmias. * **Rho-kinase inhibitors (Option C):** (e.g., Fasudil) These are used primarily in cerebral vasospasm or pulmonary hypertension. They do not have established roles in treating cardiac arrhythmias. * **Potassium channel openers (Option D):** (e.g., Nicorandil) These act as vasodilators for angina. While they affect potassium channels, they do not function as Class III anti-arrhythmics (which are potassium channel *blockers*). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Beta-blockers are the first-line treatment for chronic stable angina and for rate control in atrial fibrillation. * **Post-MI:** They are the only anti-arrhythmics proven to reduce mortality in post-myocardial infarction patients. * **Calcium Channel Blockers (Verapamil/Diltiazem):** These are the other major class that also possess both anti-anginal and anti-arrhythmic (Class IV) properties.

Q: Pulmonary fibrosis occurs most commonly due to which of the following drugs?

Amiodarone. **Explanation:** **Amiodarone** is a Class III antiarrhythmic drug known for its high iodine content and long half-life. **Pulmonary toxicity** is its most serious adverse effect, occurring in approximately 5–10% of patients. The underlying mechanism involves both direct cellular toxicity and an indirect inflammatory response (phospholipidosis), where lipids accumulate within alveolar macrophages. This leads to chronic interstitial inflammation and, ultimately, **irreversible pulmonary fibrosis**. Risk factors include a cumulative dose, older age, and pre-existing lung disease. **Analysis of Incorrect Options:** * **Clindamycin (A):** A lincosamide antibiotic primarily associated with gastrointestinal side effects, most notably *Clostridioides difficile*-associated pseudomembranous colitis. * **Nikkomycin (C):** An experimental antifungal agent that inhibits chitin synthesis; it is not associated with pulmonary fibrosis. * **Kanamycin (D):** An aminoglycoside antibiotic. Its primary toxicities are ototoxicity (vestibulocochlear nerve damage) and nephrotoxicity, not pulmonary fibrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing Pulmonary Fibrosis:** Remember the mnemonic **"B-B-M-A-T"**: **B**leomycin (most common chemotherapy cause), **B**usulfan, **M**ethotrexate, **A**miodarone, and **T**oxic Nitrofurantoin. * **Monitoring:** Patients on chronic Amiodarone therapy require baseline and periodic **Chest X-rays** and **Pulmonary Function Tests (PFTs)**. * **Amiodarone Side Effects:** Think of "6 Ps": **P**ulmonary fibrosis, **P**rolonged QT, **P**hotodermatitis (Blue-gray skin), **P**eripheral neuropathy, **P**hotophobia (corneal microdeposits), and **P**erturbed thyroid (Hypo/Hyperthyroidism).

Question 1

What is the drug of choice for ventricular arrhythmia due to myocardial infarction?

Accepted Answer

Lidocaine

Answer

Quinidine

Answer

Amiodarone

Answer

Phenytoin

Question 2

Which of the following drugs used to treat glaucoma is contraindicated in patients with urine retention?

Accepted Answer

Disopyramide

Answer

Flecainide

Answer

Lidocaine

Answer

Tocainide

Question 3

What is the mechanism by which aspirin is used for ischemic heart disease?

Accepted Answer

Inhibition of TXA2 synthesis

Answer

Inhibition of prostacyclin synthesis

Answer

Inhibition of COX 2

Answer

Inhibition of endothelin synthesis

Question 4

Which of the following is FALSE about Aliskiren?

Accepted Answer

It is a p-glycoprotein inhibitor

Answer

It is an oral renin inhibitor

Answer

It can result in hyperkalemia

Answer

It blocks the conversion of angiotensinogen to Angiotensin I

Question 5

Trimetazidine is used for which of the following conditions?

Accepted Answer

Angina

Answer

Hypertension

Answer

Congestive Heart Failure (CHF)

Answer

Arrhythmia

Question 6

Which of the following drugs can increase the calcium sensitivity of myocytes?

Accepted Answer

Levosimendan

Answer

Omapatrilat

Answer

Milrinone

Answer

Sacubitril

Question 7

Which anti-androgen is used in heart failure?

Accepted Answer

Spironolactone

Answer

Carvedilol

Answer

Sampatrilat

Answer

Abiraterone

Question 8

What is the typical time taken for digitalization in cardiac therapy?

Accepted Answer

5 days

Answer

36 hours

Answer

12 hours

Answer

10 days

Question 9

Which of the following drug classes has both anti-arrhythmic and anti-anginal properties?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Rho kinase inhibitor

Answer

Potassium channel openers

Question 10

Pulmonary fibrosis occurs most commonly due to which of the following drugs?

Accepted Answer

Amiodarone

Answer

Clindamycin

Answer

Nikkomycin

Answer

Kanamycin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?